This $447,340 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Miami to identify epigenetic dependencies and vulnerabilities in endocrine-resistant breast cancer. The key objectives are to:
-
Determine the role of the CoREST-SWI/SNF axis in endocrine-resistant breast cancer with ESR1 mutations. This includes studying the effects of CoREST inhibition, alone or in combination with SWI/SNF inhibition, on tumor burden in cell lines and animal models.
-
Investigate the role of CoREST in endocrine-resistant breast cancer with ARID1A mutations, evaluating whether CoREST inhibition can sensitize ARID1A-deficient cells to the antiestrogen drug fulvestrant.
The goal is to uncover new therapeutic targets and mechanisms to improve overall survival for patients with metastatic, endocrine-resistant breast cancer. The award period is from March 1, 2025 to February 28, 2030.
Generated 3/18/25, 2:03 AM